Association for Value-Based Cancer Care
Subscribe or Manage Preferences
Multiple myeloma (MM) is a relatively uncommon malignancy, yet it levies a substantial socioeconomic burden. In 2014, there will be an estimated 24,050 new cases of MM, with 11,090 myeloma-related deaths.
The value of any intervention for multiple myeloma (MM) must be expressed as an equation: value equals cost plus quality of care. The simplicity of this formula, however, disguises the complexity of cost calculation and quality evaluation.
Duration of therapy is an important consideration in a valuebased plan for multiple myeloma (MM). This issue has recently received more attention with the increased use of novel targeted agents.
In the treatment of patients with multiple myeloma (MM), dosing is an important but often overlooked ontributor to the value of care.
Identification, characterization, and management of osteolytic bone lesions are key aspects of care in multiple myeloma.
Multiple myeloma (MM) is among the most challenging cancers to treat. Patients diagnosed with this disease are typically older, with a mean age of 62 years for men and 61 years for women.1 This older, often elderly population is prone to several factors that complicate treatment, including comorbid conditions, decreased physiologic reserve, cognitive and other psychosocial problems, and a greater risk for adverse drug reactions.2,3
Recent clinical evidence supports new strategies for the management of patients with relapsed and refractory multiple myeloma (MM), including the use of both approved and investigational targeted agents, new dosing regimens for established therapies, and refined, individualized sequencing plans. These approaches have the potential to benefit both clinicians and payers who strive to enhance outcomes and provide value-based care in the relapsed/refractory setting.
To determine the value of treatments for multiple myeloma (MM), healthcare professionals must evaluate supporting clinical evidence.
Over the past 20 years, research in multiple myeloma (MM) has delineated the molecular and genetic mechanisms of the disease.
Over the past 2 decades, the standard of care for multiple myeloma (MM) has shifted with the introduction of novel, targeted agents such as bortezomib, lenalidomide, and thalidomide.
Page 1 of 3
Results 1 - 10 of 26
  • Personalized Medicine in Oncology
  • Value-Based Cancer Care
  • The Oncology Nurse
  • The Oncology Pharmacist
  • American Health & Drug Benefits
  • Lynx CME
  • Association for Value-Based Cancer Care
  • Oncology Practice Management